Wockhardt

Price chart

Previous close

₹2,006.30

Open

₹1,994.20

Day high

₹2,089.00

Day low

₹1,976.60

Listed on NSE since 23 February 2000.

Market value

₹31,641 Cr

P/E (trailing)

77.20

EPS (trailing)

₹25.22

Price to book

6.15

Dividend yield

0.00%

Return on equity

7.8%

Debt to equity

0.41

Profit margin

10.7%

Volume today

6.91 L

Average volume

9.22 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Wockhardt’s results filed with NSE, consolidated (the whole group). Net profit is the share of Wockhardt’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Wockhardt’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine, as well as offers insulin aspart regular and biphasic drug products. Further, the company offers delivery devices for insulin, including DispoPen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Mumbai

Employees

2,564

Company website · Profile: Yahoo Finance

No headlines name Wockhardt in the last day or two.

• Annual General Meeting

  Action · ex-date 21 June 2024

• Annual General Meeting

  Action · ex-date 7 August 2023

• Rights 3:10@ Premium Rs 220 Per Share

  Right · ex-date 8 March 2022 · record date 9 March 2022

• Annual General Meeting

  Action · ex-date 23 July 2021

• Annual General Meeting

  Action · ex-date 24 July 2020

• Annual General Meeting

  Action · ex-date 2 August 2019

• Annual General Meeting

  Action · ex-date 25 July 2018

• Annual General Meeting

  Action · ex-date 24 July 2017

Source: NSE. Latest first, 8 of 20.